Loading
Infinity Pharmaceuticals
Infinity was the Cambridge biotech that discovered duvelisib, the PI3K-delta/gamma inhibitor later approved for chronic lymphocytic leukaemia, before licensing it out and turning to eganelisib; it filed for bankruptcy in 2023.
Also called: Infinity Pharmaceuticals, Inc.Infinity
Overview
Infinity Pharmaceuticals, founded in 2001 in Cambridge, Massachusetts, developed duvelisib (IPI-145) through the phase 3 DUO trial in relapsed chronic lymphocytic leukaemia before licensing it to Verastem, which won approval in 2018. Its later PI3K-gamma inhibitor eganelisib reached phase 2 in combination with checkpoint inhibitors, and the company filed for bankruptcy in 2023. Its trials remain on ClinicalTrials.gov under Infinity as lead sponsor.
Headquarters
Cambridge, MA, US
Scorecard
All companies#220of 1245 companies, score 24
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +12
1 approved, 0 in phase 3, 0 earlier, 1 targets, 34 registry studies. Formula on the scorecards page.
Type
Stage
Wound down
Website
Founded
2001
Products
1ApprovedSmall-molecule PI3Kδ/γ inhibitor
Duvelisib · Copiktra
A dual PI3K inhibitor for relapsed CLL whose survival data raised FDA concern; use is now limited to late lines.
Connected
4Similar pages
- CompanyEmergent BioSolutions
Shares Pivotal (registrational) trial, Clinical trial, Chronic lymphocytic leukaemia.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
infi.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/